Filters

Levomefolate calcium manufacturers

Filters

None products found

drospirenone + ethinylestradiol + levomefolate calcium + levomefolate calcium

Tablets, film coated (3 mg + 0.02 mg + 0.451 mg) + 0.451 mg, (3 mg + 0.03 mg + 0.451 mg) + 0.451 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP, China
Comments
Ref : Beyaz® and Sofyral®
Manufacturer #252

This company is a leading player in the pharmaceutical industry, boasting decades of experience in research, development, and manufacturing. They specialize in the production of a wide range of pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for both human and veterinary use. Their product portfolio spans multiple therapeutic areas, including but not limited to, oncology, cardiology, and other essential therapeutic categories. They offer a comprehensive range of services, including contract manufacturing (CMO) and the production of over-the-counter (OTC) products. The company holds EU and US GMP approvals for its production lines, ensuring adherence to rigorous quality standards. Their production lines encompass various dosage forms, including solids, liquids, and injectables. Their global presence extends across Europe and North America, with a network of 10 manufacturing facilities. They have a strong commitment to research and development, with dedicated teams focusing on innovative solutions and advancements in the pharmaceutical field.

Manufacturer usually replies in 37 days

calcium citrate + levomefolate calcium + pyridoxal phosphate + vitamin d3 + methylcobalamin

Tablets 1000 mg + 210 mg + 1 mg + 20 mg + 2000 IU + 1500 mcg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #38861
India-based pharmaceutical formulations company manufacturing Rx generic oral solids, liquids, and semi-solids for domestic and regulated export markets. Dosage forms span infections, metabolic, and cardiovascular therapy areas aligned with Indian and international GMP standards. Committed to quality manufacturing and compliance for multi-market pharmaceutical distribution.

Manufacturer usually replies in 100 days

drospirenone + ethinylestradiol + levomefolate calcium

Tablets 3 mg+0.02 mg+1 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19051
This WHO GMP certified pharmaceutical company is a global player, producing a wide range of pharmaceuticals and supplements. Their state-of-the-art manufacturing facilities across the EU and North America are equipped for various dosage forms, including oral solids, injectables, liquids, and ophthalmic/nasal preparations. Key therapy areas include dermatology, cosmetics, female hormonal treatments, and antibiotics (penicillin & cephalosporins). They also produce nutraceuticals and Ayurvedic supplements. The company emphasizes quality, reliability, and sustainability in all its operations.

Manufacturer usually replies in 46 days

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Drospirenone:

Drospirenone, also known under the brand name Slynd, or in combination with oestrogen where it is commonly sold under the name Yasmin, is a progestin medication which is used in birth control pills. These pharmaceutical products are prescribed to prevent pregnancy and are also used in menopausal hormone therapy, along with the treatment of a few other indications.
Drospirenone is known as a fourth-generation progestin, with the original patent being granted to the drugs manufacturing company Schering AG in 1976 and subsequently emerged onto the medical marketplace in 2000. With drospirenone manufacturers and drospirenone suppliers being granted additional patents including WIPO and US in 1998 and 2000, respectively. More recently, the medication was approved for use in menopausal hormone therapy in combination with estradiol in 2005 and was introduced for use as a progestogen-only birth control pill in 2019.
Currently, due to the expiration of patents and its wide regulatory approval, drospirenone has become cost-effective for distributors to list for sale and wholesale on the global marketplace. As such, drospirenone, especially in combination with ethinylestradiol, has become widely available for order at a variety of price points and quantities.

Method of action of drospirenone:

Drospirenone functions through its antiandrogen effects, improving acne and hirsutism, while also inhibiting the maturation of follicles and ovulation, preventing pregnancy. It is an analogue of the diuretic spironolactone, which involves anti-mineralocorticoid activity, inhibiting aldosterone receptors, which increases sodium and water excretion. In essence, drospirenone suppresses the release of both the follicle-stimulating hormone and luteinizing hormone, preventing ovulation, while also inducing other changes which may aid in pregnancy prevention. Such as alterations in cervical mucus consistency, hindering sperm movement, and lowering the chance of embryo implantation.

Form and dosage of drospirenone:

As with other drugs, the final form and packaging are dependent on the manufacturers and suppliers, as well as the specific distributor and order. However, drospirenone is predominantly listed for sale as a combination medication along with ethinylestradiol. It comes in forms including tablets and film-coated tablets which are taken orally, with or without food. Typically for use in pregnancy prevention and menstruation regulation, it is recommended that the medication be taken once daily during the 21-day cycle, followed by 7 days abstinence. For the use in the treatment of other indications, drospirenone regimes tend to be bespoke to the needs of the specific patient, as such, the prescribing medical official’s and manufacturers’ instructions should be adhered to.

Drospirenone on Pipelinepharma:

Currently, we have found 13 trusted drospirenone manufacturers and drospirenone suppliers from our online global list of B2B sellers. These distributors have drospirenone available for order online and are located in countries including India, Brazil, the European Union, and Argentina. Each of the manufacturing and B2B wholesale companies on our online pharmaceutical products list has been verified by the Pipelinepharma team according to strict quality control. This ensures a hassle-free sourcing experience and reduces buyer mileage.

Price of drospirenone and how to buy:

Although the cost of drospirenone is highly dependent on numerous factors, a cursory search online reveals a typical B2B wholesale cost at approximately USD 18.92 for 63 tablets of drospirenone at 3 mg and ethinylestradiol at 30 micrograms. These values are for the NHS in the UK, as such are only intended for reference. Finding drospirenone manufacturers and drospirenone suppliers on the Pipelinepharma company marketplace is easy, simply search for the desired pharmaceutical products, select the listing of choice, and then press either the ‘Accept’, ‘Negotiate’, or ‘Get offer’ button on the online interface to begin a transaction.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.